Cardiology Research and Practice [8] J. Danziger, “Importance of low-grade albuminuria,” Mayo Clinic Proceedings, vol. 83, no. 7, pp. 806–812, 2008. [9] D. De Zeeuw, H. H. Parving, and R. H. Henning, “Microal- buminuria as an early marker for cardiovascular disease,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2100–2105, 2006. [10] C. Y. Hsu, C. E. McCulloch, C. Iribarren, J. Darbinian, and A. S. Go, “Body mass index and risk for end-stage renal disease,” Annals of Internal Medicine, vol. 144, no. 1, pp. 21–28, 2006. [11] R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, pp. S112–S119, 1998. [12] A. Lindner, B. Charra, D. J. Sherrard, and B. H. Scrib- ner, “Accelerated atherosclerosis in prolonged maintenance hemodialysis,” New England Journal of Medicine, vol. 290, no. 13, pp. 697–701, 1974. [13] R. Vanholder, Z. Massy, A. Argiles et al., “Chronic kidney disease as cause of cardiovascular morbidity and mortality,” Nephrology Dialysis Transplantation, vol. 20, pp. 1048–1056, 2005. [14] R. M. A. Henry, P. J. Kostense, G. Bos et al., “Mild renal insuﬃciency is associated with increased cardiovascular mortality,” Kidney International, vol. 62, no. 4, pp. 1402– 1407, 2002. [15] T. Ninomiya, Y. Kiyohara, M. Kubo et al., “Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study,” American Journal of Kidney Diseases, vol. 48, no. 3, pp. 383–391, 2006. [16] J. Chen, P. Muntner, L. L. Hamm et al., “The metabolic syndrome and chronic kidney disease in U.S. adults,” Annals of Internal Medicine, vol. 140, no. 3, pp. 167–174, 2004. [17] N. Perico, I. Codreanu, A. Schieppati, and G. Remuzzi, “Pre- vention of progression and remission/regression strategies for chronic renal diseases: can we do better now than ﬁve years ago?” Kidney International, vol. 68, no. 98, supplement, pp. S21–S24, 2005. [18] H. Bahrami, D. A. Bluemke, R. Kronmal et al., “Novel metabolic risk factors for incident heart failure and their relationship with obesity. The MESA (Multi-Ethnic Study of Atherosclerosis) Study,” Journal of the American College of Cardiology, vol. 51, no. 18, pp. 1775–1783, 2008. [19] K. Wachtell, H. Ibsen, M. H. Olsen et al., “Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study,” Annals of Internal Medicine, vol. 139, no. 11, pp. 901–906, 2003. [20] K. E. Wellen and G. S. Hotamisligil, “Obesity-induced inﬂammatory changes in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1785–1788, 2003. [21] L. K. M. Summers, J. S. Samra, and K. N. Frayn, “Impaired postprandial tissue regulation of blood ﬂow in insulin resis- tance: a determinant of cardiovascular risk?” Atherosclerosis, vol. 147, no. 1, pp. 11–15, 1999. [22] N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473– 2476, 1999. [23] Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an adipose-speciﬁc protein, adiponectin, in obesity,” Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 79–83, 1999. [24] K. Hotta, T. Funahashi, Y. Arita et al., “Plasma concentrations of a novel, adipose-speciﬁc protein, adiponectin, in type 2 7 diabetic patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1595–1599, 2000. [25] E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine organ,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548–2556, 2004. [26] A. R. Nawrocki and P. E. Scherer, “The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inﬂammation,” Current Opinion in Pharmacology, vol. 4, no. 3, pp. 281–289, 2004. [27] P. J. Havel, “Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism,” Dia- betes, vol. 53, no. 1, pp. S143–S151, 2004. [28] K. Shimada, T. Miyazaki, and H. Daida, “Adiponectin and atherosclerotic disease,” Clinica Chimica Acta, vol. 344, no. 1-2, pp. 1–12, 2004. [29] B. Becker, F. Kronenberg, J. T. Kielstein et al., “Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1091–1098, 2005. [30] C. Tsiouﬁs, K. Dimitriadis, D. Chatzis et al., “Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension,” American Journal of Cardiology, vol. 96, no. 7, pp. 946–951, 2005. [31] Y. Yano, S. Hoshide, J. Ishikawa et al., “Diﬀerential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes,” Journal of Clinical Hypertension, vol. 9, no. 10, pp. 775–782, 2007. [32] K. Sharma, S. RamachandraRao, G. Qiu et al., “Adiponectin regulates albuminuria and podocyte function in mice,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645– 1656, 2008. [33] J. Koshimura, H. Fujita, T. Narita et al., “Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy,” Biochemical and Biophysical Research Commu- nications, vol. 316, no. 1, pp. 165–169, 2004. [34] A. Jorsal, L. Tarnow, J. Frystyk et al., “Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy,” Kidney International, vol. 74, no. 5, pp. 649–654, 2008. [35] K. Sharma, “The link between obesity and albuminuria: adiponectin and podocyte dysfunction,” Kidney Interna- tional, vol. 76, no. 2, pp. 145–148, 2009. [36] V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF—a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular ﬁltration barrier,” Nephron Physiology, vol. 106, no. 2, pp. p32–p37, 2007. [37] V. Eremina, J. A. Jeﬀerson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. [38] J. M. Friedman and J. L. Halaas, “Leptin and the regulation of body weight in mammals,” Nature, vol. 395, no. 6704, pp. 763–770, 1998. [39] J. Ren, “Leptin and hyperleptinemia—from friend to foe for cardiovascular function,” Journal of Endocrinology, vol. 181, no. 1, pp. 1–10, 2004. [40] S. So¨derberg, B. Ahre´n, J. H. Jansson et al., “Leptin is associated with increased risk of myocardial infarction,” Journal of Internal Medicine, vol. 246, no. 4, pp. 409–418, 1999. [41] A. Corsonello, F. Perticone, A. Malara et al., “Leptin- dependent platelet aggregation in healthy, overweight and